Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.06 and traded as high as $1.74. Cortexyme shares last traded at $1.71, with a volume of 141,555 shares.
Cortexyme Stock Down 2.8 %
The firm has a market cap of $51.56 million, a price-to-earnings ratio of -0.58 and a beta of 1.40. The firm has a fifty day moving average price of $1.69 and a 200-day moving average price of $1.06.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- Why Invest in High-Yield Dividend Stocks?
- S&P 500 ETFs: Expense Ratios That Can Boost Your Long-Term Gains
- What Does Downgrade Mean in Investing?
- How AI Implementation Could Help MongoDB Roar Back in 2025
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
